PA8606901A1 - Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 - Google Patents

Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3

Info

Publication number
PA8606901A1
PA8606901A1 PA20048606901A PA8606901A PA8606901A1 PA 8606901 A1 PA8606901 A1 PA 8606901A1 PA 20048606901 A PA20048606901 A PA 20048606901A PA 8606901 A PA8606901 A PA 8606901A PA 8606901 A1 PA8606901 A1 PA 8606901A1
Authority
PA
Panama
Prior art keywords
optionally replaced
replaced
alquiloc1
nr9r10
members
Prior art date
Application number
PA20048606901A
Other languages
English (en)
Inventor
Eddy Jean Edgard Freyne
Marc Willems
Christopher John Love
Ludwig Paul Cooymans
Nele Vandermaesen
Peter Jaobus Johannes Antonius Buijnsters
Werner Constant Johan Embrechts
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PA8606901A1 publication Critical patent/PA8606901A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Abstract

ESTA INVENCION SE REFIERE A COMPUESTOS DE FORMULA UN N-OXIDO, UNA SAL DE ADICION FARMACEUTICAMENTE ACEPTABLE, UNA AMINA CUATERNARIA Y UNA FORMA ESTEREOQUIMICAMENTE ISOMERICA DE LOS MISMOS, DONDE EL ANILLO A REPRESENTA FENILO, PIRIDILO, PIRIMIDINILO, PIRIDAZINILO O PIRAZINILO; R1 REPRESENTA HIDROGENO; ARILO; FORMILO; ALQUILCARBONILOC1-6; ALQUILOC1-6; ALQUILOXICARBONILOC1-6; ALQUILOC1-6 SUSTITUIDO CON FORMILO, ALQUILCARBONILOC1-6, ALQUILOCICARBONILOC1-6, ALQUILCARBONILOXIC1-6; O ALQUILOXIC1-6ALQUILCARBONILOC1-6 OPCIONALMENE SISTITUIDO; X1 REPRESENTA UN ENLACE DIRECTO; -(CH2)N3- O -(CH2)N4-X1A-X1B-; R2 REPRESENTA CICLOALQUILOC3-7 OPCIONALMENTE SUSTITUIDO; FENILO; UN HETEROCICLO MONOCICLICO DE 4,5,6 O 7 MIEMBROS QUE CONTIENEN AL MENOS UN HETEROATOMO SELECCIONADO ENTRE O,S o N; BENZOXAZOLILO O UNRADICAL DE FORMULA X2 REPRESENTA UN ENLACE DIRECTO; -NR1-; -NR1-(CH2)N3-; -O-; -O-(CH2)N3-; -C(=O)-; -C(=O)- (CH2)N3-; -C(=O)-NR5-(CH2)N3; -C(=S)-; -S-; -S)=0)N1-; -(CH2)N3-; -(CH2)N4-X1A-1B-; -X1A-X1B-(CH2)N4-; -S(=O)N1-NR5-(CH2)N3-NR5-O-S(=O)N1-NR5-(CH2)N3-; R3 REPRESENTA UN HERETOCICLO MONOCICLICO DE 5 O 6 MIEMBROS OPCIONALMENTE SISTITUIDO QUE CONTIENE POR LO MENOS UN HETEROATOMO SELECCIONADO ENTRE O, S O N, O UN HETEROCICLO BICICLICO DE 9 O 10 MIEMBROS QUE CONTIENE POR LO MENOS UN HETEROATOMO SELECCIONADO ENTRE O, S O N; R4 REPRESENTA HIDROGENO; HALO; HIDROXI; ALQUILOC1-4 OPCIONALMENTE SUSTITUIDO; ALQUENILOC2-4 OPCIONALMENTE SUSTITUIDO; O ALQUINILO C2-4; POLIHALOALQUILOC1-3; ALQUILOXIC1-4 OPCIONALMENTE SUSTITUIDO; POLIHALOALQUILOXIC1-3; ALQUILTIOC1-4; POLIHALOALQUILTIOC1-3; ALQUILOXICARBONILOC1-4; ALQUILCARBONILOXIC1-4; ALQUILCARBONILOC1-4; POLIHALOALQUILCARBONILOC1-4; NITRO; CIANO; CARBOXILO; NR9R10; C(=O)NR9R10;-NR5-C(=O)-NR9R10; -NR5-C(=O)-R5; -S(=O)N1-R11; -NR5-S(=O)N1-R11; -S-CN; -NR5-CN; SU USO, COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN Y PROCESOS PARA SU PREPARACION.
PA20048606901A 2003-07-16 2004-07-15 Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3 PA8606901A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP0350314 2003-07-16

Publications (1)

Publication Number Publication Date
PA8606901A1 true PA8606901A1 (es) 2005-05-24

Family

ID=34112426

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20048606901A PA8606901A1 (es) 2003-07-16 2004-07-15 Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3

Country Status (13)

Country Link
US (1) US7449465B2 (es)
EP (1) EP1781659B1 (es)
JP (1) JP2007526894A (es)
CN (1) CN100549014C (es)
AR (1) AR045699A1 (es)
AT (1) ATE413404T1 (es)
CA (1) CA2531232A1 (es)
DE (1) DE602004017654D1 (es)
EA (1) EA011300B1 (es)
ES (1) ES2317031T3 (es)
PA (1) PA8606901A1 (es)
TW (1) TW200519115A (es)
WO (1) WO2005012304A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US7517886B2 (en) 2002-07-29 2009-04-14 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN102358738A (zh) 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
PL1660458T3 (pl) * 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
BRPI0414533A (pt) * 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
CA2580845A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
CN101083994A (zh) 2004-09-20 2007-12-05 泽农医药公司 杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
MX2007003321A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
WO2006034315A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
AR051202A1 (es) 2004-09-20 2006-12-27 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
AU2005329423A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
BRPI0517272A (pt) 2004-10-29 2008-10-07 Tibotec Pharm Ltd derivados de pirimidina bicìclicos de inibição de hiv
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
WO2006133426A2 (en) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007091107A1 (en) * 2006-02-10 2007-08-16 Summit Corporation Plc Treatment of duchenne muscular dystrophy
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
WO2009006404A2 (en) * 2007-06-29 2009-01-08 Sunesis Pharmaceuticals, Inc. Heterocyclic compounds useful as raf kinase inhibitors
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
WO2009154697A2 (en) 2008-05-28 2009-12-23 Massachusetts Institute Of Technology Disc-1 pathway activators in the control of neurogenesis
CA2742897A1 (en) 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
UY32622A (es) * 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
AU2011254550B2 (en) 2010-05-21 2013-11-07 Noviga Research Ab Novel pyrimidine derivatives
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
JP6615755B2 (ja) 2013-11-13 2019-12-04 バーテックス ファーマシューティカルズ インコーポレイテッド インフルエンザウイルスの複製の阻害剤
SI3068782T1 (sl) 2013-11-13 2018-10-30 Vertex Pharmaceuticals Incorporated Postopki za pripravo inhibitorjev v replikacije virusov gripe
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
EP3294717B1 (en) 2015-05-13 2020-07-29 Vertex Pharmaceuticals Inc. Methods of preparing inhibitors of influenza viruses replication
MX2018005342A (es) * 2015-11-02 2018-08-15 Janseen Pharmaceutica Nv Compuesto de [1,2,4]triazolo[1,5-a]pirimidin-7-ilo.
CA3041412A1 (en) * 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EP3535269B1 (en) 2016-11-02 2020-12-09 Janssen Pharmaceutica NV [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
JP7018944B2 (ja) 2016-11-02 2022-02-14 ヤンセン ファーマシューティカ エヌ．ベー． ＰＤＥ２阻害剤としての［１，２，４］トリアゾロ［１，５－ａ］ピリミジン化合物
RU2663913C1 (ru) * 2016-11-17 2018-08-13 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Твердая лекарственная форма антидиабетического препарата на основе N-замещенного производного амринона - ингибитора киназы гликогенсинтазы
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN114072397A (zh) 2019-05-10 2022-02-18 德西费拉制药有限责任公司 杂芳基氨基嘧啶酰胺自噬抑制剂及其使用方法
JP2022531801A (ja) 2019-05-10 2022-07-11 デシフェラ・ファーマシューティカルズ，エルエルシー フェニルアミノピリミジンアミドオートファジー阻害剤およびその使用方法
CN112079836B (zh) * 2019-06-13 2022-12-13 中国科学院上海药物研究所 三唑并嘧啶类化合物及其盐、组合物和应用
MX2021015628A (es) 2019-06-17 2022-04-18 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5962594A (ja) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd ３，５―ジ置換―トリアゾロピリミジン誘導体
DE69919707T2 (de) 1998-06-19 2005-09-01 Chiron Corp., Emeryville Glycogen synthase kinase 3 inhibitoren
RU2312860C2 (ru) 1999-04-15 2007-12-20 Бристол-Маерс Сквибб Компани Циклические ингибиторы протеинтирозинкиназ
ES2246927T3 (es) 1999-12-17 2006-03-01 Chiron Corporation Inhibidores biciclicos de glucogeno sintasa quinasa 3.
US20020040031A1 (en) * 2000-07-07 2002-04-04 Glasky Michelle S. Methods for prevention of accumulation of amyloid beta peptide in the central nervous system
US6737085B2 (en) * 2000-11-01 2004-05-18 Tokiwa Phytochemical Co., Ltd. Apocynum venetum extract for use as antidepressant
AU2002222293A1 (en) * 2000-12-19 2002-07-01 Smithkline Beecham P.L.C. Pyrazolo(3,4-c)pyridines as gsk-3 inhibitors
GB0100621D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VI
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives

Also Published As

Publication number Publication date
TW200519115A (en) 2005-06-16
AU2004260739A1 (en) 2005-02-10
EA011300B1 (ru) 2009-02-27
CN100549014C (zh) 2009-10-14
ATE413404T1 (de) 2008-11-15
ES2317031T3 (es) 2009-04-16
US7449465B2 (en) 2008-11-11
CA2531232A1 (en) 2005-02-10
EP1781659A2 (en) 2007-05-09
EP1781659B1 (en) 2008-11-05
AR045699A1 (es) 2005-11-09
JP2007526894A (ja) 2007-09-20
WO2005012304A2 (en) 2005-02-10
EA200600257A1 (ru) 2006-06-30
US20060183747A1 (en) 2006-08-17
CN1938308A (zh) 2007-03-28
WO2005012304A3 (en) 2007-04-26
DE602004017654D1 (de) 2008-12-18

Similar Documents

Publication Publication Date Title
PA8606901A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
PA8607001A1 (es) Derivados de triazolopirimidinas como inhibidores de la glucogeno sintasa quinasa 3
NO20071476L (no) Antidiuretiske midler.
GT200700036A (es) Compuestos fenil amido heterociclicos condensados
GT200300240A (es) Nuevos derivados de dihidropirimido (4,5-d) pirimidinona sustituida por amino, fabricacion y uso de los mismos comoagentes farmaceuticos
AR057981A1 (es) Compuesto de pirroloquinolin -4- ona, su uso para la preparacion de un medicamento, composicion farmaceutica que lo comprende y compuestos intermediarios pra su preparacion
CR9772A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos
CR11223A (es) Compuestos de biciclolactama sustituida
PA8796201A1 (es) Agentes anti-infecciosos y su uso
CR10696A (es) Compuestos de n-metilaminometil isoindol, composiciones que las comprenden y metodos que utilizan los mismos
CO6280399A2 (es) Peptidil nitrilos y uso de los mismos como inhibidores de peptidil peptidasa i
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
AR041635A1 (es) Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen
AR048039A1 (es) Profarmacos de piperazina y agentes antivirales de piperidina sustituidos
GT200600341A (es) Inhibidores macrociclicos del virus de la hepatitis c
AR032165A1 (es) Carboxamidas heterociclicas, composiciones farmaceuticas, uso de dichas carboxamidas para preparar un medicamento como agentes antivirales y el uso in vitro para inhibir una dna polimerasa viral
GT200400133AA (es) Derivados de pirrolo[3,4-c] pirazol, activos como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los comprenden. (solicitud fraccionaria no. 1, derivada de la patente no. pi-2004-0133).
GT200500323A (es) Compuestos de n-sulfonilaminobencil - 2- fenoxiacetamida sustituidos
CR9786A (es) Compuestos de bencimidazol-tiofeno
PA8623101A1 (es) Compuestos farmaceuticamente activos
PA8576001A1 (es) "difenilazetidinonas sustituidas en anillo, procedimiento para su preparacion , medicamentos que comprenden estos compuestos y su uso".
GT200300187A (es) Compuestos antiinflamatorios de di y trifluoro-triazolo-piridinas
SG162803A1 (en) Imidazole based lxr modulators
PA8573501A1 (es) Derivados de benzoxazina y su empleo
PA8587501A1 (es) Benzoxazinonas sustituidas y usos de las mismas